These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Nelfinavir (Viracept).
    Author: Baker R, Bowers M.
    Journal: BETA; 1997 Mar; ():5. PubMed ID: 11364528.
    Abstract:
    The Food and Drug Administration (FDA) is expected to grant accelerated approval for nelfinavir (Viracept) by mid-March 1997. Nelfinavir, a potent inhibitor of HIV replication when used in 3-drug therapies with AZT and 3TC, has produced undetectable viral loads and increased CD4 counts. A pediatric formulation has also been developed and the FDA has been asked to give it accelerated approval. An expanded access program is available that offers the drug free of charge to children aged 2 through 13 years. One of nelfinavir's advantages is that initial resistance to the drug does not also mean additional cross-resistance to the other protease inhibitors. A phone number is provided for further information.
    [Abstract] [Full Text] [Related] [New Search]